3Patel R,Tyring S,Strand A,et al.Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection.Sex Transm Infect 1999;75(6):398-402.
4Scott LL,Sanchez PJ,Jackson GL,et al.Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes.Obstet Gynecd 1996;87(1):69-73.
5Brocklehurst P,Kinghorn G,Carney O,et al.A randomized placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent herpes infection.Br J Obstet Gynaecol 1998; 105(3):275-280.
6CDC.1998 Guidlines for treatment of sexually transmitted disease.MMWR 1998;47:17 -39.
二级参考文献26
1Corey L, Handsfield HH. Genital herpes and public health : addressing a global problem. JAMA. 2000. 283(6) :791 -794.
2Yeung-Yue KA, Brentjens MH, Lee PC ,et al. Herpes simplex viruses 1 and 2. Dermatol Clin, 2002, 20(2) :249 -266.
3Mbizvo EM, Msuya Sia E, Stray-Pedersen B,et al. Association of herpes simplex virus type 2 with the human immunodeficiency virus among urban women in Zimbabwe. Int J STD AIDS, 2002, 13 (5) :343 - 348.
5Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis, 2000, 30(3) :549 -566.
6Morrison LA. Vaccines against genital herpes: progress and limitations. Drugs, 2002, 62(8) :1119 - 1129.
7Heineman TC, Connelly BL, Bourne N,et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol, 1995, 69(12) :8109 -8113.
8Manning WC, Paliard X, Zhou S, et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol, 1997, 71 (10) :7960 -7962.
9Smith CC, Peng T, Kulka M, et al. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10)is required for immediate-early gene expression and virus growth. J Virol. 1998. 72(11) :9131 -9141.
10Aurelian L, Kokuba H, Smith CC. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine, 1999, 17 (15-16) :1951 - 1963.
